# Registration of Idarucizumab for Patients with IntraCranial Hemorrhage

> **NCT04062097** · — · COMPLETED · sponsor: **University Hospital, Essen** · enrollment: 104 (actual)

## Conditions studied

- Intracranial Hemorrhage

## Interventions

- **DRUG:** Dabigatran Etexilate Oral Capsule [Pradaxa]
- **DRUG:** Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]
- **DRUG:** Vitamin K antagonist

## Key facts

- **NCT ID:** NCT04062097
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-19
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04062097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04062097, "Registration of Idarucizumab for Patients with IntraCranial Hemorrhage". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04062097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*